This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Research on rapamycin is in its earliest stages in brain tumors and has had very limited use in humans. Rapamycin is being used in this study because it has been shown to stop tumor cells from dividing, especialy in the setting of a particular molecular abnormality present on the tumor. Studies on animals and on tumor cells in the laboratory have shown rapamycin activity in killing tumor cells and slowing tumor growth in several types of tumors, including brain tumors. However, very little is known about the activity of rapamycin in human tumors.
Showing the most recent 10 out of 1085 publications